News

Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA Releases Draft Guidance on Residual Solvents

The US Food and Drug Administration has distributed a draft of Guidance for Industry: Residual Solvents in Drug Products Marketed in the United States for public comment.

Rockville, MD (Aug. 5)-The US Food and Drug Administration has distributed a draft of Guidance for Industry: Residual Solvents in Drug Products Marketed in the United States for public comment.

The guidance is meant to assist companies holding new drug applications (NDAs) or abbreviated new drug applications (ANDAs) for compendial products to comply with the testing requirements in the new USP General Chapter 467, which became official on July 1, 2008 (see related story, "USP 467, Residual Solvents Becomes Official"), as well as 21 CFR 314.70. The draft also aims to help manufacturers of compendial products not marketed under NDAs and ANDAs.

According to the draft guidance, among its recommendations, FDA “will require that US marketed drug products with an official USP monograph (compendial drug products) meet the residual solvents requirements in the new USP General Chapter <467>,” which provides options other than finished drug testing to evaluate compliance. The draft guidance also describes the conditions under which analytical procedures other than those described in USP <467> will be accepted.

See the complete guidance.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More